Imaging mGluR5 and Synaptic Density in Psychiatric Disorders

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

120 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-01-11

Study Completion Date

2026-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This research study is designed to look at the involvement of the glutamate system and synaptic density in depression and bipolar disorder. Each participant will undergo a screening appointment to determine study eligibility. Thereafter, the study will take 2 or 3 visits depending on schedule availability and will consist of a combination of one magnetic resonance imaging (MRI) or functional magnetic resonance imaging (fMRI) scan, one proton magnetic resonance spectroscopy (MRS) and/or one C13 MRS scans, and up to two positron emission tomography (PET) scans. Participants will also participate in cognitive testing. Depending on camera time, staff availability and subject schedule, total study participation may last 1-2 months.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Examination of Glutamate and mGluR5 in Psychiatric Disorders

NCT02727972

Major Depressive Disorder Post-Traumatic Stress Disorder Bipolar Disorder

COMPLETED NA

Neuroimaging Studies of Reward Processing in Depression

NCT03026036

Major Depressive Disorder

COMPLETED

Self Focus in Bipolar Disorder: A Functional Magnetic Resonance Imaging (fMRI) Study

NCT02253225

Bipolar Disorder Major Depression Rumination

COMPLETED

Study of Functional Networks in Resting fMRI

NCT03323073

Acute Depression Major Depressive Episode

TERMINATED NA

SV2 PET Imaging With [11C]APP311

NCT03995121

Schizophrenia and Other Psychotic Disorders Cannabis Use Disorder Healthy

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

With the recent advancements in the positron emission tomography (PET) and radioligand development, the investigators are now able to image and quantify the metabotropic glutamatergic system (mGluR5) in vivo in human subjects. The investigators propose a novel investigation using \[18F\]FPEB in depression and bipolar disorder to obtain critical data to advance the understanding of the etiology of depression and bipolar disorder and its associated symptoms of cognitive dysfunction. The findings with mGluR5 by themselves are limited. Changes in mGluR5 availability could be due to changes in synaptic density. Recently, the Yale PET center synthesized a new radioligand \[11C\]UCB-J (referred to as \[11C\]APP311 at the Yale University PET Center) that binds to synaptic vesicle glycoproteins (SV2A), which represent the number of synapses in the brain. Thus, the investigators will also measure synaptic density in the brain and relate to mGluR5 availability.

Aim 1: To determine mGluR5 availability with mood disorders compared to healthy controls as measured with PET brain imaging using \[18F\]FPEB.

Hypothesis 1: decrease in mGluR5 availability in individuals with mood disorders in regions responsible for emotional and cognitive processes, including the amygdala, hippocampus, thalamus, anterior cingulate, and frontal cortices.

Aim 2: To determine if glutamate cycling in individuals with mood disorders is altered as compared to healthy controls as measured with \[1H\]MRS and \[13C\]MRS.

Hypothesis 2: increase in glutamate number in individuals with mood disorders as compared to controls.

Aim 3: To determine if the PET alterations in the glutamatergic system of depressed individuals are associated with cognitive deficits observed in depression, including concentration, attention, and memory (cognitive testing performance), and distractibility and startle.

Hypothesis 3: positive relationship between mGluR5 availability and cognitive functioning, such that individuals with higher receptor availability will perform better on tests of concentration, attention, memory, distractibility, and startle than individuals with lower receptor availability.

Aim 4: To examine whether changes in mGluR5 availability are dependent on state, or whether the lower availability is due to trait.

Hypothesis: normalization (or increase) in mGluR5 availability in euthymia as compared to depressed state.

Aim 5: To examine synaptic density changes associated with mood disorders using \[11C\]APP311 Hypothesis 5: lower synaptic density in individuals with MDD and bipolar disorder (BD), and associations between synaptic density changes and mood severity. Investigators also hypothesize there might be a relationship between synaptic density and mGluR5 availability.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Major Depressive Disorder Bipolar Disorder Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Healthy control

60 psychiatrically-healthy subjects will be enrolled as controls may participate in MRI or fMRI, \[1H\]MRS and/or \[13C\]MRS, \[18F\]FPEB and/or \[11C\]APP311 PET scans, cognitive testing

[18F]FPEB

Intervention Type RADIATION

Radiotracer: \[18F\]FPEB

[11C]APP311

Intervention Type RADIATION

Radiotracer: \[11C\]APP311, \[11C\]UCB-J

MDD

30 subjects with major depressive disorder (MDD) may participate in MRI or fMRI, \[1H\]MRS and/or \[13C\]MRS, \[18F\]FPEB and/or \[11C\]APP311 PET scans, cognitive testing

[18F]FPEB

Intervention Type RADIATION

Radiotracer: \[18F\]FPEB

[11C]APP311

Intervention Type RADIATION

Radiotracer: \[11C\]APP311, \[11C\]UCB-J

Bipolar

30 subjects with bipolar disorder may participate in MRI or fMRI, \[1H\]MRS and/or \[13C\]MRS, \[18F\]FPEB and/or \[11C\]APP311 PET scans, cognitive testing

[18F]FPEB

Intervention Type RADIATION

Radiotracer: \[18F\]FPEB

[11C]APP311

Intervention Type RADIATION

Radiotracer: \[11C\]APP311, \[11C\]UCB-J

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

[18F]FPEB

Radiotracer: \[18F\]FPEB

Intervention Type RADIATION

[11C]APP311

Radiotracer: \[11C\]APP311, \[11C\]UCB-J

Intervention Type RADIATION

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

[11C]UCB-J

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

18-80 years old English speaking

Exclusion Criteria

* Current or past significant medical, neurological, or metabolic disorder
* history of head injury that led to significant long term decline in cognitive abilities as seen by decline in grades or work performance
* history of significant medical illness such that would contraindicate study participation based on above criteria and PI/MD history review
* Active, significant suicidal ideation
* Implanted metallic devices or any MR contraindications
* women who are pregnant or breastfeeding
* Met Diagnostic and Statistical Manual of Mental Disorders(DSM)-5 criteria for mild substance use disorder in the past 6 months or moderate to severe substance use disorder within the past year (except marijuana or nicotine)
* history of prior radiation exposure for research purposes within the past year such that participation in this study would place them over FDA limits for annual radiation exposure. This guideline is an effective dose of 5 rem received per year
* Current, past, or anticipated exposure to radiation in the work place within one year of proposed research PET scans
* Blood donation within 8 weeks of the start of the study
* History of a bleeding disorder or currently taking anticoagulants (such as Coumadin, Heparin, Pradaxa, Xarelto)

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No